2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 263

Efficacy of Ketoprofen Vs Ibuprofen and Diclofenac: A Systematic Review of the Literature and Meta-Analysis
Abstract Number: 963

Efficacy of Long-Term Milnacipran Treatment in Patients Meeting Different Thresholds of Clinically Relevant Pain Relief: Subgroup Analysis of a Double-Blind, Placebo-Controlled Discontinuation Study
Abstract Number: 366

Efficacy of Methotrexate (MTX) According to Anti-Citrullinated Protein Antibody (ACPA) Status in an Early Inflammatory Arthritis Cohort
Abstract Number: 1591

Efficacy of Neoprene Wrist Supports for Patients with Rheumatoid Arthritis
Abstract Number: 2372

Efficacy of Quantitative Analysis of Brainstem Atrophy On Magnetic Resonance Imaging for Diagnosis of Chronic Progressive Neuro-Behçet’s Disease
Abstract Number: 220

Efficacy of Rituximab for the Treatment of Refractory Inflammatory Myopathies Associated with Anti-Histidyl-tRNA Synthetase Antibodies (the FORCE Jo1 Study)
Abstract Number: 2076

Efficacy of the Potent PI3K-δ,γ Inhibitor IPI-145 in Rat Adjuvant Arthritis
Abstract Number: 1212

Elevated Fecal Secretory Immunoglobulin A, Anti-Cyclic Citrullinated Peptide Antibodies, and Cytokine Levels in Rheumatoid Arthritis Patients
Abstract Number: 2336

Elevated Frequency of Synovial Interleukin-21⁺ CD4⁺ T Cells Co-Expressing Tumor Necrosis Factor-a in Rheumatoid Arthritis
Abstract Number: 2199

Elevated IgG4 Serum Levels Among Primary Sjogren’s Syndrome Patients: Do They Unmask Underlying IgG4-Related Disease?
Abstract Number: 1951

Elevated Level of Tumor Necrosis Factor-Like Weak Inducer of Apoptosis in Patients with Polymyositis or Dermatomyositis
Abstract Number: 619

Elevated Plasma Levels of CXCL2 and CXCL10 Have Distinct Predictive Value in Systemic Lupus Erythematosus
Abstract Number: 2656

Elevated Serum Follistatin-Like Protein 1 Suggests an Interleukin-1 Independent Pathway for Inflammation in Patients with Cryopyrin Associated Periodic Syndromes
Abstract Number: 1915

Elevated Serum Homocysteine Levels Were Related Not with Serum Uric Acid Levels but with Decreased Renal Function in Chronic Gouty Patients
Abstract Number: 2496

Elevated Serum Level of the Vascular Endothelial Growth Factor Is Highly Predictive for New Syndesmophytes Formation in Patients with Ankylosing Spondylitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].